Canaccord Genuity has revised its price target for Boston Scientific's stock, attributing the adjustment to a slowdown in the sales of the Watchman device. The financial services firm has expressed concerns regarding the performance of this particular product, which is designed for patients with atrial fibrillation. This change in price target reflects Canaccord's analysis of the current market conditions and sales trends associated with Boston Scientific's offerings.
Don't miss out on breaking stories and in-depth articles.
